Pharma BD Deal Intelligence
AstraZeneca acquired ZS Pharma for $2.7B for hyperkalemia treatment.
AstraZeneca completes acquisition of ZS Pharma on December 17 2015 with 86.6 percent of outstanding shares validly tendered in the offer.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca acquired ZS Pharma for $2.7B for hyperkalemia treatment.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / ZS Pharma Inc. (this deal) | 2015 | $2.7B | 72 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2015 deals · AstraZeneca PLC deals · Cardiovascular deals